_400mg_logo-header.png){kind=logo}
Tyronib® (imatinib mesylate) 400mg is specially designed to:
Help your medicine get to where it needs to be
Tyronib® (Imatinb Mesylate), is a targeted therapy used to treat certain types of Leukaemia and soft tissue sarcoma, it may also be used to treat other types of cancers as part of research trial.
Tyronib® (Imatinib Mesylate) may be used to treat:- Chronic myeloid leukaemia (CML)
- A type of acute lymphoblastic leukaemia (ALL) called Philadelphia chromosome positive (Ph+ ALL)
- Gastro-intestinal stromal tumours (GISTs)
- A rare type of soft tissue cancer called dermatofibrosarcoma protuberans (DFSP)
- Other types of cancers as part of a research trial.
Imatinib is also used to treat adults for:
- Myelodysplastic / myeloproliferative diseases (MDS/MPD).:-These are a group of blood diseases in which some blood cells start growing out of control.
- Aggressive systemic mastocytosis (ASM).:-It is a cancer in which certain blood cells, called "mast" cells, grow out of control.
- Hypereosinophilic syndrome (HES) and or chronic eosinophilic leukaemia (CEL).:-These are blood diseases in which some blood cells, named "eosinophils", start growing out of control.
- Gastro-intestinal stromal tumours (GIST).:-This is a type of cancer of the stomach and bowels. This cancer affects the tissue that surrounds the stomach and bowels and the cells grow uncontrollably.
- Dermatofibrosarcoma protuberans (DFSP).:-DFSP is a cancer of the tissue beneath the skin in which some cells start growing out of control.
Uses
Tyronib® (Imatinb Mesylate), is a targeted therapy used to treat certain types of Leukaemia and soft tissue sarcoma, it may also be used to treat other types of cancers as part of research trial.
Tyronib® (Imatinib Mesylate) may be used to treat:
- Chronic myeloid leukaemia (CML)
- A type of acute lymphoblastic leukaemia (ALL) called Philadelphia chromosome positive (Ph+ ALL)
- Gastro-intestinal stromal tumours (GISTs)
- A rare type of soft tissue cancer called dermatofibrosarcoma protuberans (DFSP)
- Other types of cancers as part of a research trial.
Important Safety Information
-
Pregnancy Category D:Imatinib can cause fetal harm when administered to a pregnant woman. There have been post-market reports of spontaneous abortions and infant congenital anomalies from women who have taken Imatinib.
There are no adequate and well-controlled studies with Imatinib in pregnant women. Women should be advised not to become pregnant when taking Imatinib. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. - Nursing Mothers:Imatinib and its active metabolite are excreted into human milk. Based on data from three breastfeeding women taking Imatinib, the milk:plasma ratio is about 0.5 for imatinib and about 0.9 for the active metabolite.
- Pediatric Use:Imatinib safety and efficacy have been demonstrated in children with newly diagnosed Ph+ chronic phase CML and Ph+ ALL. There are no data in children under 1 year of age.
- Geriatric Use: In the CML clinical studies, approximately 20% of patients were older than 65 years. In the study of patients with newly diagnosed CML, 6% of patients were older than 65 years. No difference was observed in the safety profile in patients older than 65 years as compared to younger patients, with the exception of a higher frequency of edema. The efficacy of Imatinib was similar in older and younger patients.
